Traws Pharma (NASDAQ:TRAW) Earns “Buy” Rating from HC Wainwright

Traws Pharma (NASDAQ:TRAW)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 403.14% from the stock’s current price.

Several other equities research analysts have also commented on TRAW. LADENBURG THALM/SH SH upgraded shares of Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. Weiss Ratings lowered shares of Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Traws Pharma Stock Down 9.7%

Shares of NASDAQ:TRAW opened at $1.59 on Wednesday. The firm has a market capitalization of $16.15 million, a price-to-earnings ratio of -0.94 and a beta of 1.47. The stock’s 50 day moving average is $1.68 and its 200-day moving average is $1.84. Traws Pharma has a twelve month low of $1.00 and a twelve month high of $3.27.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.39. Equities research analysts anticipate that Traws Pharma will post -2.51 earnings per share for the current fiscal year.

Insider Transactions at Traws Pharma

In related news, major shareholder Orbimed Advisors Llc acquired 597,729 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The stock was acquired at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the acquisition, the insider owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 14.00% of the company’s stock.

Institutional Trading of Traws Pharma

A number of large investors have recently added to or reduced their stakes in TRAW. Two Sigma Investments LP lifted its stake in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after purchasing an additional 5,955 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after purchasing an additional 18,213 shares in the last quarter. State Street Corp purchased a new position in shares of Traws Pharma in the fourth quarter valued at $29,000. Adage Capital Partners GP L.L.C. grew its position in shares of Traws Pharma by 121.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after purchasing an additional 400,000 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Traws Pharma in the fourth quarter valued at $175,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.